Key result
Pharmacological VTE thromboprophylaxis remains underused in Asian populations given lower baseline incidence and higher bleeding risks.
Why the study?
There is a recognized gap between international guidelines strongly recommending anticoagulant prophylaxis for high-risk patients and actual practice in East and Southeast Asia.
Is routine pharmacological VTE prophylaxis appropriate for East and Southeast Asian patients given their specific risk-benefit profile?
Is routine pharmacological VTE prophylaxis appropriate for East and Southeast Asian patients given their specific risk-benefit profile?
Routine pharmacological VTE prophylaxis may have an unfavorable risk-benefit ratio in East and Southeast Asian populations due to lower baseline VTE risk and higher bleeding risk compared to Western populations.
Persistent VTE prophylaxis underuse in East/Southeast Asia may raise event risk; leaves open effective, region-specific implementation strategies.
Anticoagulant prophylaxis for high-risk patients is strongly recommended in standard clinical practice guidelines worldwide. However, there is a recognized gap between these international mandates and actual practice in East and Southeast Asia. This narrative review summarizes the underlying factors contributing to this underutilization of venous thromboembolism (VTE) thromboprophylaxis among countries in this region. Firstly, the baseline VTE incidence in general Asian population is lower than that of Western population. While historical VTE rates after major orthopedic surgery in Asia aligned with those reported in the West, recent data demonstrate that absolute event rates have decreased significantly following the adoption of modern surgical techniques, early ambulation and mechanical prophylaxis. Similarly, in general surgery, VTE disease burden is notably lower in Asian cohorts at equivalent Caprini scores compared to Western demographics. Furthermore, while Western VTE risk assessment models are available, they lack rigorous validation and calibration specifically for Asian medical patients. Regarding the safety concern, Asians show higher baseline incidence of spontaneous intracranial hemorrhage and carry a greater risk of major bleeding after warfarin administration at the same intensity. Together, these data shift the risk-benefit ratio of routine pharmacological thromboprophylaxis in Asian patients. Finally, the economic burden of routine anticoagulants for all patients at risk remains high in developing countries. We propose that, as an initial effort, institutions should establish their own consensus-based VTE prevention protocols, prioritizing at least the universal implementation of non-pharmacological prophylaxis. Ultimately, more large-scale research specifically targeting Asians is needed to formulate robust evidence-based regional recommendations.
No takes yet. Share an insight, caveat, or question.
Chiasakul et al. (2026) conducted a review in Venous thromboembolism. Pharmacological thromboprophylaxis was evaluated. Routine pharmacological VTE thromboprophylaxis is underutilized in East and Southeast Asian populations due to lower baseline VTE incidence and higher bleeding risks compared to Western cohorts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: